Sign In
Last checked at 
4 Feb 2020 16:25
genedrive plc
("genedrive" or the "Company")
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that today David Budd, Chief Executive Officer, acquired 43,330 ordinary shares of 1.5p each ("Ordinary Shares") in the Company at a price of 11.5p per share and Chris Yates, Non-Executive Director, acquired 25,000 Ordinary Shares at 11.56p per share.
Following these purchases, David Budd is interested in 188,710 Ordinary Shares, 0.5% of the issued share capital of the Company, and Chris Yates is interested in 41,304 Ordinary Shares, 0.1% of the issued share capital of the Company.
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a. | Name | 1. David Budd 2. Chris Yates
| ||||
2. | Reason for the notification | |||||
a. | Position/status | 1. Chief Executive Officer 2. Non-Executive Director | ||||
a. | Initial notification /Amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a. | Name | genedrive plc | ||||
b. | LEI | 213800ZYODIRZ87Y4K14 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a. | Description of the Financial instrument, type of instrument Identification code | Ordinary shares of 1.5 pence each
GB00B1VKB244 | ||||
b. | Nature of the transaction | Purchase | ||||
c. | Price(s) and volume(s) |
| ||||
d. | Aggregated information ·; Aggregated volume ·; Price
|
N/A
| ||||
e. | Date of the transaction | 2020-02-04 | ||||
f. | Place of the transaction | London Stock Exchange, AIM | ||||
For further details please contact:
genedrive plc | +44 (0)161 989 0245 |
David Budd: CEO / Matthew Fowler: CFO | |
Peel Hunt LLP (Nominated Adviser and Joint Broker) | +44 (0)20 7418 8900 |
James Steel / Oliver Jackson | |
Stanford Capital Partners Limited (Joint Broker) | +44 (0)20 3815 8880 |
Patrick Claridge / John Howes | |
Walbrook PR Ltd (Media Relations & Investor Relations) | +44 (0)20 7933 8780 or genedrive@walbrookpr.com |
Paul McManus / Anna Dunphy | +44 (0)7980 541 893 / +44 (0)7876 741 001 |
Follow the stocks
